Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum WELL Health Technologies Corp T.WELL

Alternate Symbol(s):  T.WELL.DB | WHTCF

WELL Health Technologies Corp. is a practitioner-focused digital healthcare company. The Company develops technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. Its business units include Canadian Patient Services, WELL Health USA Patient Services and SaaS and Technology Services. WELL Health USA Patient and... see more

TSX:WELL - Post Discussion

WELL Health Technologies Corp > WELL stock wins price target raise at Beacon
View:
Post by danche on Nov 15, 2023 3:47pm

WELL stock wins price target raise at Beacon

On November 14, WELL reported its Q3, 2023 results. The company posted Adjusted EBITDA of $28.2-million on revenue of $204.5-million, a topline that was up 40.2 per cent at the time of publication.

“Q3 was an outstanding quarter for us, as we achieved record patient visits, Adjusted EBITDA(1) and posted our first quarter ever with more than $200M in revenues,” CEO Hamed Shahbazi said. “While all our business units are executing extremely well, our Canadian business grew its Adjusted EBITDA by 24 per cent and shows no signs of slowing down. We are expecting to have strong performance for the remainder of 2023 and into next year. We are ahead of our plan for reaching one billion in revenue and feel confident in introducing our guidance for 2024 of achieving over $900-million in annual revenue driven by organic growth. The backbone of our success has been the company’s continued focus on tech enabling health care providers and supporting them in simplifying their work lives, modernizing, and digitizing their clinical practices and delivering the best health care possible.”

Leung says he believes WELL is looking to grow its topline aggressively, pointing to the company’s 2024 revenue guidance of more than $900-million.

“We believe the company’s near-term focus will be on increasing market share rather than margin accretion given the significant land grab opportunity (notably in Canadian primary care), along with the sticky nature of its service offering,” the analyst said. “Overall, we believe Q3 results were another positive data point highlighting the company’s healthy organic growth augmented by M&A. While margin improvements might be muted over the near term due to organic / M&A growth investments, we believe it will ultimately to the benefit of the company’s competitive positioning.”

In a research update to clients November 14, Leung maintained his “Buy” rating but raised his one-year price target on the stock from $6.25 to $7.00, implying a return of 59 per cent at the time of publication.

The analyst thinks WELL will post revenue of $766-million in fiscal 2023. He expects the topline will improve to $911.4-million the following year.

https://www.cantechletter.com/2023/11/well-stock-wins-price-target-raise-at-beacon/#

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities